Answers are grounded in this paper and cite their sources.
Genetic profiling study demonstrates improved chemotherapy outcomes with specific mutations in acute myeloid leukemia, highlighting potential for personalized risk stratification.
We found that DNMT3A and NPM1 mutations and MLL translocations predicted an improved outcome with high-dose induction chemotherapy in patients with AML. These findings suggest that mutational profiling could potentially be used for risk stratification and to inform prognostic and therapeutic decisions regarding patients with AML. (Funded by the National Cancer Institute and others.).
No takes yet. Share an insight, caveat, or question.
Patel et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: